カテゴリー： Market Monitor Global, 世界, 医療/バイオ

弱毒水痘生ワクチン接種の世界市場見通し2023年-2029年

◆英語タイトル：Varicella Attenuated Live Vaccination Market, Global Outlook and Forecast 2023-2029
	◆商品コード：MMG23LY8735 ◆発行会社（リサーチ会社）：Market Monitor Global ◆発行日：2023年7月（※2025年版があります。お問い合わせください。） ◆ページ数：75 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品＆ヘルスケア

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥468,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥608,400	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥702,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Varicella Attenuated Live Vaccination Market 調査レポートは次の情報を含め、グローバルにおけるの弱毒水痘生ワクチン接種市場規模と予測を収録しています。・世界の弱毒水痘生ワクチン接種市場：売上、2018年-2023年、2024年-2029年
・世界の弱毒水痘生ワクチン接種市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の弱毒水痘生ワクチン接種市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「一価ワクチン」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

弱毒水痘生ワクチン接種のグローバル主要企業は、Merck、 BCHT、 Shanghai Institute、 GSK、 Keygen、 Green Cross、 Biken、 Shanghai Rongsheng Biotech、 Changshengなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、弱毒水痘生ワクチン接種のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の弱毒水痘生ワクチン接種市場：タイプ別、2018年-2023年、2024年-2029年
世界の弱毒水痘生ワクチン接種市場：タイプ別市場シェア、2022年
・一価ワクチン、混合ワクチン

世界の弱毒水痘生ワクチン接種市場：用途別、2018年-2023年、2024年-2029年
世界の弱毒水痘生ワクチン接種市場：用途別市場シェア、2022年
・子供、大人

世界の弱毒水痘生ワクチン接種市場：地域・国別、2018年-2023年、2024年-2029年
世界の弱毒水痘生ワクチン接種市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における弱毒水痘生ワクチン接種のグローバル売上、2018年-2023年
・主要企業における弱毒水痘生ワクチン接種のグローバル売上シェア、2022年
・主要企業における弱毒水痘生ワクチン接種のグローバル販売量、2018年-2023年
・主要企業における弱毒水痘生ワクチン接種のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Merck、 BCHT、 Shanghai Institute、 GSK、 Keygen、 Green Cross、 Biken、 Shanghai Rongsheng Biotech、 Changsheng

*************************************************************

・調査・分析レポートの概要
弱毒水痘生ワクチン接種市場の定義
市場セグメント
世界の弱毒水痘生ワクチン接種市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の弱毒水痘生ワクチン接種市場規模
世界の弱毒水痘生ワクチン接種市場規模：2022年 VS 2029年
世界の弱毒水痘生ワクチン接種市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの弱毒水痘生ワクチン接種の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の弱毒水痘生ワクチン接種製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：一価ワクチン、混合ワクチン
弱毒水痘生ワクチン接種のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：子供、大人
弱毒水痘生ワクチン接種の用途別グローバル売上・予測

・地域別市場分析
地域別弱毒水痘生ワクチン接種市場規模 2022年と2029年
地域別弱毒水痘生ワクチン接種売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Merck、 BCHT、 Shanghai Institute、 GSK、 Keygen、 Green Cross、 Biken、 Shanghai Rongsheng Biotech、 Changsheng
...

A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
This report aims to provide a comprehensive presentation of the global market for Varicella Attenuated Live Vaccination, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Varicella Attenuated Live Vaccination. This report contains market size and forecasts of Varicella Attenuated Live Vaccination in global, including the following market information:
Global Varicella Attenuated Live Vaccination Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Varicella Attenuated Live Vaccination Market Sales, 2018-2023, 2024-2029, (Units)
Global top five Varicella Attenuated Live Vaccination companies in 2022 (%)
The global Varicella Attenuated Live Vaccination market was valued at US$ 2627.5 million in 2022 and is projected to reach US$ 3182.5 million by 2029, at a CAGR of 2.8% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For the major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in the ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.
The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied the largest sales market share with about 58% in 2019. It is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Varicella Attenuated Live Vaccination manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Varicella Attenuated Live Vaccination Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (Units)
Global Varicella Attenuated Live Vaccination Market Segment Percentages, by Type, 2022 (%)
Monovalent Vaccine
Combination Vaccine
Global Varicella Attenuated Live Vaccination Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (Units)
Global Varicella Attenuated Live Vaccination Market Segment Percentages, by Application, 2022 (%)
Children
Adults
Global Varicella Attenuated Live Vaccination Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (Units)
Global Varicella Attenuated Live Vaccination Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Varicella Attenuated Live Vaccination revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Varicella Attenuated Live Vaccination revenues share in global market, 2022 (%)
Key companies Varicella Attenuated Live Vaccination sales in global market, 2018-2023 (Estimated), (Units)
Key companies Varicella Attenuated Live Vaccination sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changsheng
Outline of Major Chapters:
Chapter 1: Introduces the definition of Varicella Attenuated Live Vaccination, market overview.
Chapter 2: Global Varicella Attenuated Live Vaccination market size in revenue and volume.
Chapter 3: Detailed analysis of Varicella Attenuated Live Vaccination manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Varicella Attenuated Live Vaccination in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Varicella Attenuated Live Vaccination capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Varicella Attenuated Live Vaccination Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Varicella Attenuated Live Vaccination Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Varicella Attenuated Live Vaccination Overall Market Size
2.1 Global Varicella Attenuated Live Vaccination Market Size: 2022 VS 2029
2.2 Global Varicella Attenuated Live Vaccination Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Varicella Attenuated Live Vaccination Sales: 2018-2029
3 Company Landscape
3.1 Top Varicella Attenuated Live Vaccination Players in Global Market
3.2 Top Global Varicella Attenuated Live Vaccination Companies Ranked by Revenue
3.3 Global Varicella Attenuated Live Vaccination Revenue by Companies
3.4 Global Varicella Attenuated Live Vaccination Sales by Companies
3.5 Global Varicella Attenuated Live Vaccination Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Varicella Attenuated Live Vaccination Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Varicella Attenuated Live Vaccination Product Type
3.8 Tier 1, Tier 2 and Tier 3 Varicella Attenuated Live Vaccination Players in Global Market
3.8.1 List of Global Tier 1 Varicella Attenuated Live Vaccination Companies
3.8.2 List of Global Tier 2 and Tier 3 Varicella Attenuated Live Vaccination Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Varicella Attenuated Live Vaccination Market Size Markets, 2022 & 2029
4.1.2 Monovalent Vaccine
4.1.3 Combination Vaccine
4.2 By Type – Global Varicella Attenuated Live Vaccination Revenue & Forecasts
4.2.1 By Type – Global Varicella Attenuated Live Vaccination Revenue, 2018-2023
4.2.2 By Type – Global Varicella Attenuated Live Vaccination Revenue, 2024-2029
4.2.3 By Type – Global Varicella Attenuated Live Vaccination Revenue Market Share, 2018-2029
4.3 By Type – Global Varicella Attenuated Live Vaccination Sales & Forecasts
4.3.1 By Type – Global Varicella Attenuated Live Vaccination Sales, 2018-2023
4.3.2 By Type – Global Varicella Attenuated Live Vaccination Sales, 2024-2029
4.3.3 By Type – Global Varicella Attenuated Live Vaccination Sales Market Share, 2018-2029
4.4 By Type – Global Varicella Attenuated Live Vaccination Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Varicella Attenuated Live Vaccination Market Size, 2022 & 2029
5.1.2 Children
5.1.3 Adults
5.2 By Application – Global Varicella Attenuated Live Vaccination Revenue & Forecasts
5.2.1 By Application – Global Varicella Attenuated Live Vaccination Revenue, 2018-2023
5.2.2 By Application – Global Varicella Attenuated Live Vaccination Revenue, 2024-2029
5.2.3 By Application – Global Varicella Attenuated Live Vaccination Revenue Market Share, 2018-2029
5.3 By Application – Global Varicella Attenuated Live Vaccination Sales & Forecasts
5.3.1 By Application – Global Varicella Attenuated Live Vaccination Sales, 2018-2023
5.3.2 By Application – Global Varicella Attenuated Live Vaccination Sales, 2024-2029
5.3.3 By Application – Global Varicella Attenuated Live Vaccination Sales Market Share, 2018-2029
5.4 By Application – Global Varicella Attenuated Live Vaccination Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Varicella Attenuated Live Vaccination Market Size, 2022 & 2029
6.2 By Region – Global Varicella Attenuated Live Vaccination Revenue & Forecasts
6.2.1 By Region – Global Varicella Attenuated Live Vaccination Revenue, 2018-2023
6.2.2 By Region – Global Varicella Attenuated Live Vaccination Revenue, 2024-2029
6.2.3 By Region – Global Varicella Attenuated Live Vaccination Revenue Market Share, 2018-2029
6.3 By Region – Global Varicella Attenuated Live Vaccination Sales & Forecasts
6.3.1 By Region – Global Varicella Attenuated Live Vaccination Sales, 2018-2023
6.3.2 By Region – Global Varicella Attenuated Live Vaccination Sales, 2024-2029
6.3.3 By Region – Global Varicella Attenuated Live Vaccination Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Varicella Attenuated Live Vaccination Revenue, 2018-2029
6.4.2 By Country – North America Varicella Attenuated Live Vaccination Sales, 2018-2029
6.4.3 US Varicella Attenuated Live Vaccination Market Size, 2018-2029
6.4.4 Canada Varicella Attenuated Live Vaccination Market Size, 2018-2029
6.4.5 Mexico Varicella Attenuated Live Vaccination Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Varicella Attenuated Live Vaccination Revenue, 2018-2029
6.5.2 By Country – Europe Varicella Attenuated Live Vaccination Sales, 2018-2029
6.5.3 Germany Varicella Attenuated Live Vaccination Market Size, 2018-2029
6.5.4 France Varicella Attenuated Live Vaccination Market Size, 2018-2029
6.5.5 U.K. Varicella Attenuated Live Vaccination Market Size, 2018-2029
6.5.6 Italy Varicella Attenuated Live Vaccination Market Size, 2018-2029
6.5.7 Russia Varicella Attenuated Live Vaccination Market Size, 2018-2029
6.5.8 Nordic Countries Varicella Attenuated Live Vaccination Market Size, 2018-2029
6.5.9 Benelux Varicella Attenuated Live Vaccination Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Varicella Attenuated Live Vaccination Revenue, 2018-2029
6.6.2 By Region – Asia Varicella Attenuated Live Vaccination Sales, 2018-2029
6.6.3 China Varicella Attenuated Live Vaccination Market Size, 2018-2029
6.6.4 Japan Varicella Attenuated Live Vaccination Market Size, 2018-2029
6.6.5 South Korea Varicella Attenuated Live Vaccination Market Size, 2018-2029
6.6.6 Southeast Asia Varicella Attenuated Live Vaccination Market Size, 2018-2029
6.6.7 India Varicella Attenuated Live Vaccination Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Varicella Attenuated Live Vaccination Revenue, 2018-2029
6.7.2 By Country – South America Varicella Attenuated Live Vaccination Sales, 2018-2029
6.7.3 Brazil Varicella Attenuated Live Vaccination Market Size, 2018-2029
6.7.4 Argentina Varicella Attenuated Live Vaccination Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Varicella Attenuated Live Vaccination Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Varicella Attenuated Live Vaccination Sales, 2018-2029
6.8.3 Turkey Varicella Attenuated Live Vaccination Market Size, 2018-2029
6.8.4 Israel Varicella Attenuated Live Vaccination Market Size, 2018-2029
6.8.5 Saudi Arabia Varicella Attenuated Live Vaccination Market Size, 2018-2029
6.8.6 UAE Varicella Attenuated Live Vaccination Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Merck
7.1.1 Merck Company Summary
7.1.2 Merck Business Overview
7.1.3 Merck Varicella Attenuated Live Vaccination Major Product Offerings
7.1.4 Merck Varicella Attenuated Live Vaccination Sales and Revenue in Global (2018-2023)
7.1.5 Merck Key News & Latest Developments
7.2 BCHT
7.2.1 BCHT Company Summary
7.2.2 BCHT Business Overview
7.2.3 BCHT Varicella Attenuated Live Vaccination Major Product Offerings
7.2.4 BCHT Varicella Attenuated Live Vaccination Sales and Revenue in Global (2018-2023)
7.2.5 BCHT Key News & Latest Developments
7.3 Shanghai Institute
7.3.1 Shanghai Institute Company Summary
7.3.2 Shanghai Institute Business Overview
7.3.3 Shanghai Institute Varicella Attenuated Live Vaccination Major Product Offerings
7.3.4 Shanghai Institute Varicella Attenuated Live Vaccination Sales and Revenue in Global (2018-2023)
7.3.5 Shanghai Institute Key News & Latest Developments
7.4 GSK
7.4.1 GSK Company Summary
7.4.2 GSK Business Overview
7.4.3 GSK Varicella Attenuated Live Vaccination Major Product Offerings
7.4.4 GSK Varicella Attenuated Live Vaccination Sales and Revenue in Global (2018-2023)
7.4.5 GSK Key News & Latest Developments
7.5 Keygen
7.5.1 Keygen Company Summary
7.5.2 Keygen Business Overview
7.5.3 Keygen Varicella Attenuated Live Vaccination Major Product Offerings
7.5.4 Keygen Varicella Attenuated Live Vaccination Sales and Revenue in Global (2018-2023)
7.5.5 Keygen Key News & Latest Developments
7.6 Green Cross
7.6.1 Green Cross Company Summary
7.6.2 Green Cross Business Overview
7.6.3 Green Cross Varicella Attenuated Live Vaccination Major Product Offerings
7.6.4 Green Cross Varicella Attenuated Live Vaccination Sales and Revenue in Global (2018-2023)
7.6.5 Green Cross Key News & Latest Developments
7.7 Biken
7.7.1 Biken Company Summary
7.7.2 Biken Business Overview
7.7.3 Biken Varicella Attenuated Live Vaccination Major Product Offerings
7.7.4 Biken Varicella Attenuated Live Vaccination Sales and Revenue in Global (2018-2023)
7.7.5 Biken Key News & Latest Developments
7.8 Shanghai Rongsheng Biotech
7.8.1 Shanghai Rongsheng Biotech Company Summary
7.8.2 Shanghai Rongsheng Biotech Business Overview
7.8.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccination Major Product Offerings
7.8.4 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccination Sales and Revenue in Global (2018-2023)
7.8.5 Shanghai Rongsheng Biotech Key News & Latest Developments
7.9 Changsheng
7.9.1 Changsheng Company Summary
7.9.2 Changsheng Business Overview
7.9.3 Changsheng Varicella Attenuated Live Vaccination Major Product Offerings
7.9.4 Changsheng Varicella Attenuated Live Vaccination Sales and Revenue in Global (2018-2023)
7.9.5 Changsheng Key News & Latest Developments
8 Global Varicella Attenuated Live Vaccination Production Capacity, Analysis
8.1 Global Varicella Attenuated Live Vaccination Production Capacity, 2018-2029
8.2 Varicella Attenuated Live Vaccination Production Capacity of Key Manufacturers in Global Market
8.3 Global Varicella Attenuated Live Vaccination Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Varicella Attenuated Live Vaccination Supply Chain Analysis
10.1 Varicella Attenuated Live Vaccination Industry Value Chain
10.2 Varicella Attenuated Live Vaccination Upstream Market
10.3 Varicella Attenuated Live Vaccination Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Varicella Attenuated Live Vaccination Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Varicella Attenuated Live Vaccination in Global Market
Table 2. Top Varicella Attenuated Live Vaccination Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Varicella Attenuated Live Vaccination Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Varicella Attenuated Live Vaccination Revenue Share by Companies, 2018-2023
Table 5. Global Varicella Attenuated Live Vaccination Sales by Companies, (Units), 2018-2023
Table 6. Global Varicella Attenuated Live Vaccination Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Varicella Attenuated Live Vaccination Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Varicella Attenuated Live Vaccination Product Type
Table 9. List of Global Tier 1 Varicella Attenuated Live Vaccination Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Varicella Attenuated Live Vaccination Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Varicella Attenuated Live Vaccination Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Varicella Attenuated Live Vaccination Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Varicella Attenuated Live Vaccination Sales (Units), 2018-2023
Table 15. By Type - Global Varicella Attenuated Live Vaccination Sales (Units), 2024-2029
Table 16. By Application – Global Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Varicella Attenuated Live Vaccination Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Varicella Attenuated Live Vaccination Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Varicella Attenuated Live Vaccination Sales (Units), 2018-2023
Table 20. By Application - Global Varicella Attenuated Live Vaccination Sales (Units), 2024-2029
Table 21. By Region – Global Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Varicella Attenuated Live Vaccination Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Varicella Attenuated Live Vaccination Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Varicella Attenuated Live Vaccination Sales (Units), 2018-2023
Table 25. By Region - Global Varicella Attenuated Live Vaccination Sales (Units), 2024-2029
Table 26. By Country - North America Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Varicella Attenuated Live Vaccination Sales, (Units), 2018-2023
Table 29. By Country - North America Varicella Attenuated Live Vaccination Sales, (Units), 2024-2029
Table 30. By Country - Europe Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Varicella Attenuated Live Vaccination Sales, (Units), 2018-2023
Table 33. By Country - Europe Varicella Attenuated Live Vaccination Sales, (Units), 2024-2029
Table 34. By Region - Asia Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Varicella Attenuated Live Vaccination Sales, (Units), 2018-2023
Table 37. By Region - Asia Varicella Attenuated Live Vaccination Sales, (Units), 2024-2029
Table 38. By Country - South America Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Varicella Attenuated Live Vaccination Sales, (Units), 2018-2023
Table 41. By Country - South America Varicella Attenuated Live Vaccination Sales, (Units), 2024-2029
Table 42. By Country - Middle East & Africa Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Varicella Attenuated Live Vaccination Sales, (Units), 2018-2023
Table 45. By Country - Middle East & Africa Varicella Attenuated Live Vaccination Sales, (Units), 2024-2029
Table 46. Merck Company Summary
Table 47. Merck Varicella Attenuated Live Vaccination Product Offerings
Table 48. Merck Varicella Attenuated Live Vaccination Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. Merck Key News & Latest Developments
Table 50. BCHT Company Summary
Table 51. BCHT Varicella Attenuated Live Vaccination Product Offerings
Table 52. BCHT Varicella Attenuated Live Vaccination Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. BCHT Key News & Latest Developments
Table 54. Shanghai Institute Company Summary
Table 55. Shanghai Institute Varicella Attenuated Live Vaccination Product Offerings
Table 56. Shanghai Institute Varicella Attenuated Live Vaccination Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Shanghai Institute Key News & Latest Developments
Table 58. GSK Company Summary
Table 59. GSK Varicella Attenuated Live Vaccination Product Offerings
Table 60. GSK Varicella Attenuated Live Vaccination Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. GSK Key News & Latest Developments
Table 62. Keygen Company Summary
Table 63. Keygen Varicella Attenuated Live Vaccination Product Offerings
Table 64. Keygen Varicella Attenuated Live Vaccination Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Keygen Key News & Latest Developments
Table 66. Green Cross Company Summary
Table 67. Green Cross Varicella Attenuated Live Vaccination Product Offerings
Table 68. Green Cross Varicella Attenuated Live Vaccination Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. Green Cross Key News & Latest Developments
Table 70. Biken Company Summary
Table 71. Biken Varicella Attenuated Live Vaccination Product Offerings
Table 72. Biken Varicella Attenuated Live Vaccination Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. Biken Key News & Latest Developments
Table 74. Shanghai Rongsheng Biotech Company Summary
Table 75. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccination Product Offerings
Table 76. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccination Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. Shanghai Rongsheng Biotech Key News & Latest Developments
Table 78. Changsheng Company Summary
Table 79. Changsheng Varicella Attenuated Live Vaccination Product Offerings
Table 80. Changsheng Varicella Attenuated Live Vaccination Sales (Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. Changsheng Key News & Latest Developments
Table 82. Varicella Attenuated Live Vaccination Production Capacity (Units) of Key Manufacturers in Global Market, 2021-2023 (Units)
Table 83. Global Varicella Attenuated Live Vaccination Capacity Market Share of Key Manufacturers, 2021-2023
Table 84. Global Varicella Attenuated Live Vaccination Production by Region, 2018-2023 (Units)
Table 85. Global Varicella Attenuated Live Vaccination Production by Region, 2024-2029 (Units)
Table 86. Varicella Attenuated Live Vaccination Market Opportunities & Trends in Global Market
Table 87. Varicella Attenuated Live Vaccination Market Drivers in Global Market
Table 88. Varicella Attenuated Live Vaccination Market Restraints in Global Market
Table 89. Varicella Attenuated Live Vaccination Raw Materials
Table 90. Varicella Attenuated Live Vaccination Raw Materials Suppliers in Global Market
Table 91. Typical Varicella Attenuated Live Vaccination Downstream
Table 92. Varicella Attenuated Live Vaccination Downstream Clients in Global Market
Table 93. Varicella Attenuated Live Vaccination Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Varicella Attenuated Live Vaccination Segment by Type in 2022
Figure 2. Varicella Attenuated Live Vaccination Segment by Application in 2022
Figure 3. Global Varicella Attenuated Live Vaccination Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Varicella Attenuated Live Vaccination Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Varicella Attenuated Live Vaccination Revenue, 2018-2029 (US$, Mn)
Figure 7. Varicella Attenuated Live Vaccination Sales in Global Market: 2018-2029 (Units)
Figure 8. The Top 3 and 5 Players Market Share by Varicella Attenuated Live Vaccination Revenue in 2022
Figure 9. By Type - Global Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Varicella Attenuated Live Vaccination Revenue Market Share, 2018-2029
Figure 11. By Type - Global Varicella Attenuated Live Vaccination Sales Market Share, 2018-2029
Figure 12. By Type - Global Varicella Attenuated Live Vaccination Price (US$/Unit), 2018-2029
Figure 13. By Application - Global Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Varicella Attenuated Live Vaccination Revenue Market Share, 2018-2029
Figure 15. By Application - Global Varicella Attenuated Live Vaccination Sales Market Share, 2018-2029
Figure 16. By Application - Global Varicella Attenuated Live Vaccination Price (US$/Unit), 2018-2029
Figure 17. By Region - Global Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Varicella Attenuated Live Vaccination Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Varicella Attenuated Live Vaccination Revenue Market Share, 2018-2029
Figure 20. By Region - Global Varicella Attenuated Live Vaccination Sales Market Share, 2018-2029
Figure 21. By Country - North America Varicella Attenuated Live Vaccination Revenue Market Share, 2018-2029
Figure 22. By Country - North America Varicella Attenuated Live Vaccination Sales Market Share, 2018-2029
Figure 23. US Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Varicella Attenuated Live Vaccination Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Varicella Attenuated Live Vaccination Sales Market Share, 2018-2029
Figure 28. Germany Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2029
Figure 29. France Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Varicella Attenuated Live Vaccination Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Varicella Attenuated Live Vaccination Sales Market Share, 2018-2029
Figure 37. China Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2029
Figure 41. India Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Varicella Attenuated Live Vaccination Revenue Market Share, 2018-2029
Figure 43. By Country - South America Varicella Attenuated Live Vaccination Sales Market Share, 2018-2029
Figure 44. Brazil Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Varicella Attenuated Live Vaccination Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Varicella Attenuated Live Vaccination Sales Market Share, 2018-2029
Figure 48. Turkey Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Varicella Attenuated Live Vaccination Revenue, (US$, Mn), 2018-2029
Figure 52. Global Varicella Attenuated Live Vaccination Production Capacity (Units), 2018-2029
Figure 53. The Percentage of Production Varicella Attenuated Live Vaccination by Region, 2022 VS 2029
Figure 54. Varicella Attenuated Live Vaccination Industry Value Chain
Figure 55. Marketing Channels

※参考情報

弱毒水痘生ワクチンとは、水痘ウイルスを弱毒化した生ワクチンであり、主に水痘（帯状疱疹の原因ともなる）の予防を目的として使用されます。このワクチンは、感染した場合に起こる症状を軽減し、重篤な合併症を防ぐための重要な手段です。

水痘ウイルスは、主に空気感染や接触感染を通じて広がります。感染すると、発熱やかゆみを伴う皮膚の発疹が出現します。通常は軽度の疾患とされていますが、特に免疫力が低下している人や妊婦、乳幼児においては重篤な合併症が生じることがあります。そのため、予防接種が推奨されています。

弱毒水痘生ワクチンの特徴は、ウイルスが生きていながら、病原性が極めて低くなっている点です。このため、ワクチン接種を受けた人の体内でウイルスが軽い感染を引き起こし、免疫系が反応することにより、自然感染に類似した免疫応答が得られます。これにより、実際の水痘ウイルスに再感染した場合にも、強力な防御が期待できるのです。

たとえば、ワクチン接種後、通常は軽微な副反応が見られますが、これはなんらかの形で体がウイルスに反応している証拠です。副反応としては、接種部位の腫れや発赤、軽度の発熱、皮疹などが挙げられますが、これらは通常数日内に収束します。重篤な副反応は非常に稀です。

弱毒水痘生ワクチンにはいくつかの種類がありますが、代表的なものには、バリセリワクチン（Varivax）や、麻疹・風疹・水痘混合ワクチン（MMRV）が含まれます。バリセリワクチンは単独で水痘を予防するために使用され、MMRVは麻疹や風疹と一緒に接種することで、多様な感染症に対する予防効果を一度に得ることができます。

用途としては、主に小児に対する予防接種が挙げられます。日本では、1歳から2歳の間に接種することが推奨されており、特に集団生活を送る子どもたちにとって重要です。また、成人においても、過去に水痘を経験していない場合や、リスクが高い人々に対して接種が勧められています。接種によって得られる免疫は長期間持続するとされており、再接種は不要とされていますが、個々の健康状態やリスクに応じた医師との相談が推奨されます。

関連技術としては、細胞培養技術や遺伝子工学技術が挙げられます。弱毒化においては、ウイルスの遺伝子を改変することで病原性を削減する方法が研究されています。最近では、ワクチンの効率性を高めるためのアジュバント技術や、mRNAワクチンのような新しい技術が冒険されることがありますが、水痘ウイルスに関しては現在でも弱毒化生ワクチンが主流です。

ワクチンの導入によって、発症率は飛躍的に低下し、重篤な合併症を引き起こすリスクも減少しています。これにより、世界中で水痘の管理が改善され、多くの国々で公衆衛生上の成功を収めているのです。しかし、ワクチン接種率が低下すると、水痘ウイルスが再び広がり、集団感染が発生する可能性があるため、定期的な接種推進が重要です。

このように、弱毒水痘生ワクチンは、水痘に対する効果的な予防策として幅広く利用されており、今後もその重要性が期待されます。公衆衛生の観点から、ワクチンの普及促進や新たな研究が行われることで、さらに安全で効果的なワクチンが開発されることが望ましいといえるでしょう。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 弱毒水痘生ワクチン接種の世界市場見通し2023年-2029年(Varicella Attenuated Live Vaccination Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

弱毒水痘生ワクチン接種の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp